Vanegas Emanuel, Robles-Velasco Karla, Osorio María F, Farfán Bajaña María José, Sarfraz Zouina, Sarfraz Azza, Fernández Cadena Juan Carlos, Andrade Molina Derly Madeleiny, Panchana Lascano Matias, Cherrez-Ojeda Ivan
Universidad Espíritu Santo, Samborondón, Ecuador.
Respiralab Research Group, Guayaquil, Ecuador.
Ann Med Surg (Lond). 2021 Dec;72:103044. doi: 10.1016/j.amsu.2021.103044. Epub 2021 Nov 18.
Limited large-scale studies have been conducted to investigate the adverse effects of COVID-19 vaccine in Latin America, particularly among the healthcare worker (HCW) population in Ecuador. The objective of this study was to assess a cohort of Ecuadorian healthcare workers for adverse reactions following vaccination with the Pfizer-BioNTech vaccine.
We conducted an observational cross-sectional study to assess the potential adverse reactions to the Pfizer-BioNTech COVID-19 vaccine among a sample of healthcare workers (HCWs) in the city of Guayaquil, Ecuador, from March to May 2021.
The sample comprised 1291 patients, with a mean age of 39.3 years (SD, 13.5). In general, 79% (N = 1020) of participants presented an adverse effect of any type at first dose, while 75.1% (N = 969) did so at the second dose. Pain at the puncture site was the most common adverse effect overall after either the first (68.4%) and second (55.6%) dose. Regarding anaphylaxis, no participant developed the condition after the first dose, and only 0.2% (N = 2) developing it at the second dose. No fatalities were reported.
Our findings suggest that adverse reactions following COVID-19 vaccination with the Pfizer-BioNTech vaccine are relatively common, albeit often mild and self-limited. Consistent with the literature there were few cases of anaphylaxis, and no deaths that could be attributed to the inoculation with the vaccine. We hope our findings can help to reassure the public that benefits of vaccination highly outweigh the risks and contribute to the effort of reducing vaccine hesitancy among those who are concerned about the safety and potential side effects.
在拉丁美洲，针对新冠疫苗不良反应开展的大规模研究有限，尤其是在厄瓜多尔的医护人员群体中。本研究的目的是评估一组接种辉瑞 - 生物科技公司疫苗后的厄瓜多尔医护人员的不良反应情况。
我们进行了一项观察性横断面研究，以评估2021年3月至5月期间厄瓜多尔瓜亚基尔市医护人员样本中对辉瑞 - 生物科技公司新冠疫苗的潜在不良反应。
样本包括1291名患者，平均年龄为39.3岁（标准差为13.5）。总体而言，79%（N = 1020）的参与者在第一剂后出现了任何类型的不良反应，而在第二剂后出现不良反应的比例为75.1%（N = 969）。穿刺部位疼痛是第一剂（68.4%）和第二剂（55.6%）后总体上最常见的不良反应。关于过敏反应，没有参与者在第一剂后出现该症状，只有0.2%（N = 2）在第二剂后出现。未报告死亡病例。
我们的研究结果表明，接种辉瑞 - 生物科技公司的新冠疫苗后的不良反应相对常见，尽管通常症状较轻且为自限性。与文献一致，过敏反应病例很少，且没有可归因于接种疫苗的死亡病例。我们希望我们的研究结果有助于让公众放心，接种疫苗的益处远大于风险，并有助于减少那些担心疫苗安全性和潜在副作用的人群中的疫苗犹豫现象。
